Search

Abstract Four isomeric, homoleptic iridium(III) metal complexes bearing 5‐(trifluoromethyl)imidazo[4,5‐b]pyridin‐2‐ylidene and 6‐(trifluoromethyl)imidazo[4,5‐b]pyridin‐2‐ylidene‐based cyclometalating chelates are successfully synthesized. The meridional isomers can be converted to facial isomers through acid induced isomerization. The m‐isomers display a relatively broadened and red‐shifted emission, while f‐isomers exhibit narrowed blue emission band, together with higher photoluminescent quantum yields and reduced radiative lifetime relative to the mer‐counterparts. Maximum external quantum efficiencies of 13.5% and 22.8% are achieved for the electrophosphorescent devices based on f‐tpb1 and m‐tpb1 as dopant emitter together with CIE coordinates of (0.15, 0.23) and (0.22, 0.45), respectively. By using f‐tpb1 as the sensitizing phosphor and t‐DABNA as thermally activated delayed fluorescence (TADF) terminal emitter, hyperluminescent OLEDs are successfully fabricated, giving high efficiency of 29.6%, full width at half maximum (FWHM) of 30 nm, and CIE coordinates of (0.13, 0.11), confirming the efficient Förster resonance energy transfer (FRET) process.

Early diagnosis of acute diseases is restricted by the sensitivity and complex process of sample treatment. Here, an ultrasensitive, rapid, and portable electrochemiluminescence‐microfluidic (ECL‐M) system is described via sandwich‐type immunoassay and surface plasmonic resonance (SPR) assay. Using a sandwich immunoreaction approach, the ECL‐M system employs cardiac troponin‐I antigen (cTnI) as a detection model with a Ru@SiO2 NPs labeled antibody as the signal probe. For miR‐499‐5p detection, gold nanoparticles generate SPR effects to enhance Ru(bpy)32+ ECL signals. The system based on alternating current (AC) electroosmotic flow achieves an LOD of 2 fg mL−1 for cTnI in 5 min and 10 aM for miRNAs in 10 min at room temperature. The point‐of‐care testing (POCT) device demonstrated 100% sensitivity and 98% specificity for cTnI detection in 123 clinical serum samples. For miR‐499‐5p, it exhibited 100% sensitivity and 97% specificity in 55 clinical serum samples. Continuous monitoring of these biomarkers in rats' saliva, urine, and interstitial fluid samples for 48 hours revealed observations rarely documented in biotic fluids. The ECL‐M POCT device stands as a top‐performing system for ECL analysis, offering immense potential for ultrasensitive, rapid, highly accurate, and facile detection and monitoring of acute diseases in POC settings. [ABSTRACT FROM AUTHOR]